Phase I/II trial of YHI-1003 plus Capecitabine
Phase 1
- Conditions
- Refractory Advanced Colorectal Cancer
- Registration Number
- JPRN-jRCT2080221670
- Lead Sponsor
- Yakult Honsha Co.,Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
(1)Patients with recurrent or metastatic colorectal cancer
(2)Patients must have failed available therapy for the treatment of advanced colorectal cancer.
(3)No prior exposure to capecitabine and S-1
(4)ECOG performance status (PS) :0-1
Exclusion Criteria
(1)Patients with uncontrolled intercurrent illness
(2)Female patients who are pregnant or lactating
(3)Patients with known central nervous system CNS metastases
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method